Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates.
Protease inhibitors used in combination with reverse transcriptase inhibitors have demonstrated potent anti-HIV-1 activity in vitro as well as in vivo. We evaluated interactions among five protease inhibitors: indinavir (IDV), ritonavir (RTV), saquinavir (SQV), amprenavir (APV), and nelfinavir (NFV), when used in combinations of two and three drugs in vitro against several HIV-1 isolates, including those susceptible and resistant to various nucleoside and nonnucleoside reverse transcriptase inhibitors. Interactions ranged from synergy to slight antagonism depending on the viral isolates and the experimental conditions employed. Further clinical evaluation of protease inhibitor combinations is warranted.
Tremblay
C
C
Infectious Diseases Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Merrill
D P
DP
Chou
T C
TC
Hirsch
M S
MS
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors